Company Description
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific.
The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.
It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications.
The company sells its products through local distributors.
InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Country | IL |
IPO Date | Apr 12, 2011 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 65 |
CEO | Marvin L. Slosman |
Contact Details
Address: 4 Menorat Hamaor Street Tel Aviv, IL | |
Website | https://www.inspiremd.com |
Stock Details
Ticker Symbol | NSPR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001433607 |
CUSIP Number | 45779A853 |
ISIN Number | US45779A8466 |
Employer ID | 26-2123838 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Marvin L. Slosman | President, Chief Executive Officer & Director |
Andrea Tommasoli | Chief Operating Officer |
Craig Shore | Chief Financial Officer, Chief Administrative Officer, Secretary & Treasurer |
Amir Kohen | Senior Vice President of Finance & HR |
Dr. Patrick A. Verta DVM, M.D., MS Stat | Executive Vice President of Clinical & Medical Affairs |
Dr. Sol J. Barer Ph.D. | Special Advisor to the Board |
Pete J. Ligotti | Executive Vice President & GM of North America |
Shane Thomas Gleason | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 12, 2024 | 8-K | Current Report |
Dec 09, 2024 | 8-K | Current Report |
Dec 04, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 27, 2024 | 3 | Filing |
Nov 25, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
Nov 12, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Oct 28, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |